{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:31:15Z","timestamp":1787319075118,"version":"build-2736575974"},"reference-count":54,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Despite advances in vaccination and the use of antiviral treatments, patients with hematologic malignancies, including B-cell lymphoproliferative disorders, are particularly vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The recent introduction of bispecific antibodies (BsAbs) in the treatment algorithm of relapsed\/refractory B-cell non-Hodgkin lymphoma (B-NHL) has raised concerns regarding their impact on COVID-19 outcomes. This study aimed to evaluate the impact of SARS-CoV-2 infection on treatment outcomes in patients receiving BsAbs. We assessed the severity of COVID-19 and SARS-CoV-2 serostatus, with antibody titers measured before, during, and after BsAbs administration. A total of 109 patients with B-NHL treated with BsAbs from March 2020 to January 2023 were included. SARS-CoV-2 infection was observed in 56 patients (51%), with 36% experiencing prolonged viral shedding, causing therapy delays in 78% of patients and permanent discontinuations in 19%. Regarding COVID-19 severity, 36% of patients presented moderate, 20% severe, and 12% critical disease. Seven patients (13%) died owing to COVID-19 pneumonia. Similar to observations with anti-CD20 monoclonal antibodies, BsAbs were associated with negative antispike serostatus for at least 6 months after treatment completion. Importantly, this lack of seroconversion was linked with severe disease and increased mortality. These findings underscore important considerations for the management of patients receiving BsAbs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015406","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T09:50:22Z","timestamp":1747907422000},"page":"4180-4189","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7532-9634","authenticated-orcid":false,"given":"\u00c1ngel","family":"Serna","sequence":"first","affiliation":[{"name":"1Servei d\u2019Hematologia, Vall d\u2019Hebron Hospital Universitari, Experimental Hematology, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"},{"name":"2Departament de Medicina, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-4605","authenticated-orcid":false,"given":"V\u00edctor","family":"Navarro","sequence":"additional","affiliation":[{"name":"3Statistics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1444-8562","authenticated-orcid":false,"given":"Moraima","family":"Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"1Servei d\u2019Hematologia, Vall d\u2019Hebron Hospital Universitari, Experimental Hematology, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"},{"name":"2Departament de Medicina, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9909-3715","authenticated-orcid":false,"given":"Josu","family":"Iraola-Truchuelo","sequence":"additional","affiliation":[{"name":"1Servei d\u2019Hematologia, Vall d\u2019Hebron Hospital Universitari, Experimental Hematology, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bosch","sequence":"additional","affiliation":[{"name":"1Servei d\u2019Hematologia, Vall d\u2019Hebron Hospital Universitari, Experimental Hematology, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"},{"name":"2Departament de Medicina, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4180-4713","authenticated-orcid":false,"given":"Cristina","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"1Servei d\u2019Hematologia, Vall d\u2019Hebron Hospital Universitari, Experimental Hematology, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"},{"name":"2Departament de Medicina, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1774-679X","authenticated-orcid":false,"given":"Anna","family":"Falc\u00f3","sequence":"additional","affiliation":[{"name":"4Department of Infectious Diseases, Vall d\u2019Hebron Hospital Universitari, Vall d\u2019Hebron Research Institute, Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9852-5574","authenticated-orcid":false,"given":"Adaia","family":"Albasanz","sequence":"additional","affiliation":[{"name":"4Department of Infectious Diseases, Vall d\u2019Hebron Hospital Universitari, Vall d\u2019Hebron Research Institute, Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Ruiz-Camps","sequence":"additional","affiliation":[{"name":"4Department of Infectious Diseases, Vall d\u2019Hebron Hospital Universitari, Vall d\u2019Hebron Research Institute, Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Andr\u00e9s","sequence":"additional","affiliation":[{"name":"5Department of Microbiology, Vall d\u2019Hebron Hospital Universitari, Vall d\u2019Hebron Research Institute, Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1476-0815","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Ant\u00f3n","sequence":"additional","affiliation":[{"name":"5Department of Microbiology, Vall d\u2019Hebron Hospital Universitari, Vall d\u2019Hebron Research Institute, Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1326-1341","authenticated-orcid":false,"given":"Juliana","family":"Esperalba","sequence":"additional","affiliation":[{"name":"5Department of Microbiology, Vall d\u2019Hebron Hospital Universitari, Vall d\u2019Hebron Research Institute, Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainara","family":"Ferrero","sequence":"additional","affiliation":[{"name":"6Hematology Department, University Hospital Arnau de Vilanova, Lleida, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9670-0495","authenticated-orcid":false,"given":"Tom\u00e1s","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"6Hematology Department, University Hospital Arnau de Vilanova, Lleida, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9346-0134","authenticated-orcid":false,"given":"Cecilia","family":"Carpio","sequence":"additional","affiliation":[{"name":"1Servei d\u2019Hematologia, Vall d\u2019Hebron Hospital Universitari, Experimental Hematology, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"},{"name":"2Departament de Medicina, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7732-7808","authenticated-orcid":false,"given":"Marta","family":"Crespo","sequence":"additional","affiliation":[{"name":"1Servei d\u2019Hematologia, Vall d\u2019Hebron Hospital Universitari, Experimental Hematology, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"},{"name":"2Departament de Medicina, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0805-9288","authenticated-orcid":false,"given":"Gloria","family":"Iacoboni","sequence":"additional","affiliation":[{"name":"1Servei d\u2019Hematologia, Vall d\u2019Hebron Hospital Universitari, Experimental Hematology, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"},{"name":"2Departament de Medicina, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7592-6815","authenticated-orcid":false,"given":"Ana","family":"Mar\u00edn-Niebla","sequence":"additional","affiliation":[{"name":"1Servei d\u2019Hematologia, Vall d\u2019Hebron Hospital Universitari, Experimental Hematology, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"},{"name":"2Departament de Medicina, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Bosch","sequence":"additional","affiliation":[{"name":"1Servei d\u2019Hematologia, Vall d\u2019Hebron Hospital Universitari, Experimental Hematology, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"},{"name":"2Departament de Medicina, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Abrisqueta","sequence":"additional","affiliation":[{"name":"1Servei d\u2019Hematologia, Vall d\u2019Hebron Hospital Universitari, Experimental Hematology, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"},{"name":"2Departament de Medicina, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"issue":"3","key":"2025082608215220900_bib1","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3324\/haematol.2022.281421","article-title":"Treatment patterns and outcomes in relapsed\/refractory follicular lymphoma: results from the international SCHOLAR-5 study","volume":"108","author":"Ghione","year":"2023","journal-title":"Haematologica"},{"issue":"16","key":"2025082608215220900_bib2","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [published correction appears in Blood. 2018;131(5):587-588]","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2025082608215220900_bib3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"issue":"14","key":"2025082608215220900_bib4","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.3390\/cells12141858","article-title":"Redefining precision management of r\/r large B-cell lymphoma: novel antibodies take on CART and BMT in the quest for future treatment strategies","volume":"12","author":"Dada","year":"2023","journal-title":"Cells"},{"issue":"19","key":"2025082608215220900_bib5","first-page":"2307","article-title":"5-year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1)","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025082608215220900_bib6","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1182\/blood-2021-148948","article-title":"Two-year follow-up of Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R\/R) large B-cell lymphomas (LBCL)","volume":"138","author":"Abramson","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2025082608215220900_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"2025082608215220900_bib8","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3390\/biomedicines10081960","article-title":"CAR T-based therapies in lymphoma: a review of current practice and perspectives","volume":"10","author":"Sheikh","year":"2022","journal-title":"Biomedicines"},{"key":"2025082608215220900_bib9","doi-asserted-by":"crossref","first-page":"2021-2-4","DOI":"10.7573\/dic.2021-2-4","article-title":"Bispecific antibodies for non-Hodgkin\u2019s lymphomas and multiple myeloma","volume":"10","author":"Castaneda-Puglianini","year":"2021","journal-title":"Drugs Context"},{"issue":"24","key":"2025082608215220900_bib10","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMe2212732","article-title":"Bispecific antibodies in lymphoma \u2014 another win for T cells","volume":"387","author":"Bartlett","year":"2022","journal-title":"N Engl J Med"},{"key":"2025082608215220900_bib11","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"2025082608215220900_bib12","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"24","key":"2025082608215220900_bib13","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2025082608215220900_bib14","article-title":"A phase 2 study of REGN1979, an anti-CD20 x anti-CD3 bispecific antibody (Ab), in patients with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (B-NHL)","volume":"134","author":"Topp","year":"2019","journal-title":"Blood"},{"key":"2025082608215220900_bib15","doi-asserted-by":"crossref","first-page":"100810","DOI":"10.1016\/j.blre.2021.100810","article-title":"Bispecific antibody therapy, its use and risks for infection: bridging the knowledge gap","volume":"49","author":"Longhitano","year":"2021","journal-title":"Blood Rev"},{"issue":"1","key":"2025082608215220900_bib16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","article-title":"COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association survey (EPICOVIDEHA)","volume":"14","author":"Pagano","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"9","key":"2025082608215220900_bib17","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1007\/s00277-023-05315-1","article-title":"COVID-19 infection outcomes in patients receiving CD20 targeting T-cell engaging bispecific antibodies for B-cell non-Hodgkin lymphoma","volume":"102","author":"Nachar","year":"2023","journal-title":"Ann Hematol"},{"issue":"27","key":"2025082608215220900_bib18","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"2025082608215220900_bib19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med Overseas Ed"},{"issue":"23","key":"2025082608215220900_bib20","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2025082608215220900_bib21","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1038\/s41375-021-01270-w","article-title":"COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia","volume":"35","author":"Roeker","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"2025082608215220900_bib22","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41408-021-00528-x","article-title":"Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia","volume":"11","author":"Parry","year":"2021","journal-title":"Blood Cancer J"},{"issue":"8","key":"2025082608215220900_bib23","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S2352-3026(21)00199-X","article-title":"Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma","volume":"8","author":"Lim","year":"2021","journal-title":"Lancet Haematol"},{"issue":"9","key":"2025082608215220900_bib24","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.2021012443","article-title":"Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell\u2013directed therapies","volume":"138","author":"Ghione","year":"2021","journal-title":"Blood"},{"key":"2025082608215220900_bib25","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.20.20071423","article-title":"Detection of nucleocapsid antibody to SARS-CoV-2 is more sensitive than antibody to spike protein in COVID-19 patients","author":"Burbelo","year":"24  2020","journal-title":"medRxiv"},{"key":"2025082608215220900_bib26","unstructured":"World Health organization\n          . Clinical management of COVID-19: living guideline, 23 June 2022. Updated 15 September 2022. Accessed 1 March 2023. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-clinical-2022-1."},{"key":"2025082608215220900_bib27","doi-asserted-by":"crossref","first-page":"100812","DOI":"10.1016\/j.nmni.2020.100812","article-title":"COVID-19 reinfection: prolonged shedding or true reinfection?","volume":"38","author":"Falahi","year":"2020","journal-title":"New Microbes New Infect"},{"issue":"3","key":"2025082608215220900_bib28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cmi.2020.11.028","article-title":"Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity","volume":"27","author":"Yahav","year":"2021","journal-title":"Clin Microbiol Infection"},{"issue":"25","key":"2025082608215220900_bib29","doi-asserted-by":"crossref","first-page":"683","DOI":"10.15585\/mmwr.mm7225a3","article-title":"Trends in laboratory-confirmed SARS-CoV-2 reinfections and associated hospitalizations and deaths among adults aged \u226518 years - 18 U.S. jurisdictions, September 2021-December 2022","volume":"72","author":"Ma","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"2025082608215220900_bib30","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.3201\/eid2808.220617","article-title":"Early SARS-CoV-2 reinfections within 60 days and implications for retesting policies","volume":"28","author":"Nevejan","year":"2022","journal-title":"Emerging Infect Dis"},{"issue":"5","key":"2025082608215220900_bib31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.5501\/wjv.v9.i5.79","article-title":"Reinfection risk of novel coronavirus (CoVID-19): a systematic review of current evidence","volume":"9","author":"SeyedAlinaghi","year":"2020","journal-title":"World J Virol"},{"issue":"3","key":"2025082608215220900_bib32","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jinf.2020.06.067","article-title":"SARS-CoV-2 detection, viral load and infectivity over the course of an infection","volume":"81","author":"Walsh","year":"2020","journal-title":"J Infect"},{"issue":"15","key":"2025082608215220900_bib33","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/cid\/ciaa351","article-title":"Factors associated with prolonged viral RNA shedding in patients with coronavirus disease 2019 (COVID-19)","volume":"71","author":"Xu","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2025082608215220900_bib34","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/ejh.13493","article-title":"Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies","volume":"105","author":"Sanchez-Pina","year":"2020","journal-title":"Eur J Haematol"},{"issue":"25","key":"2025082608215220900_bib35","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"issue":"20","key":"2025082608215220900_bib36","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 \u2014 preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"2025082608215220900_bib37","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.vaccine.2021.02.007","article-title":"A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine","volume":"39","author":"Chu","year":"2021","journal-title":"Vaccine"},{"issue":"6","key":"2025082608215220900_bib38","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"2025082608215220900_bib39","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jtct.2021.06.024","article-title":"Safety and immunogenicity of the BNT162b2 MRNA COVID-19 vaccine in patients after allogeneic HCT or CD19-based CART therapy\u2014a single-center prospective cohort study","volume":"27","author":"Ram","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"8","key":"2025082608215220900_bib40","first-page":"e583","article-title":"Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study","volume":"8","author":"Maneikis","year":"2021","journal-title":""},{"issue":"25","key":"2025082608215220900_bib41","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 safety and efficacy of AZD1222 (ChAdOx1 NCoV-19) Covid-19 vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"2025082608215220900_bib42","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/bloodadvances.2021006101","article-title":"Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies","volume":"6","author":"Jim\u00e9nez","year":"2022","journal-title":"Blood Adv"},{"key":"2025082608215220900_bib43","doi-asserted-by":"crossref","first-page":"101965","DOI":"10.1016\/j.eclinm.2023.101965","article-title":"Vaccines and therapeutics for immunocompromised patients with COVID-19","volume":"59","author":"Shoham","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2025082608215220900_bib44","doi-asserted-by":"crossref","first-page":"e068632","DOI":"10.1136\/bmj-2021-068632","article-title":"Efficacy of Covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ"},{"issue":"1","key":"2025082608215220900_bib45","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1182\/blood.2021013445","article-title":"Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients","volume":"139","author":"Liebers","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2025082608215220900_bib46","doi-asserted-by":"crossref","first-page":"E312","DOI":"10.1002\/ajh.26626","article-title":"Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: an EPICOVIDEHA survey report","volume":"97","author":"Blennow","year":"2022","journal-title":"Am J Hematol"},{"issue":"3","key":"2025082608215220900_bib47","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/S2666-5247(23)00336-1","article-title":"SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis","volume":"5","author":"Raglow","year":"2024","journal-title":"Lancet Microbe"},{"key":"2025082608215220900_bib48","doi-asserted-by":"crossref","first-page":"100210","DOI":"10.1016\/j.clinpr.2022.100210","article-title":"Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: retrospective cohort study and literature review","volume":"16","author":"Hettle","year":"2022","journal-title":"Clin Infect Pract"},{"issue":"3","key":"2025082608215220900_bib49","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/bjh.19143","article-title":"Prolonged shedding of viable SARS-CoV-2 in immunocompromised patients with haematological malignancies: a prospective study","volume":"204","author":"Ichikawa","year":"2023","journal-title":"Br J Haematol"},{"key":"2025082608215220900_bib50","doi-asserted-by":"crossref","first-page":"860891","DOI":"10.3389\/fimmu.2022.860891","article-title":"Persistence of SARS-CoV-2 infection in severely immunocompromised patients with complete remission B-cell lymphoma and anti-CD20 monoclonal antibody therapy: a case report of two cases","volume":"13","author":"Mart\u00ednez-Chinchilla","year":"2022","journal-title":"Front Immunol"},{"issue":"11","key":"2025082608215220900_bib51","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/s41409-023-02069-2","article-title":"Outcomes of allogeneic hematopoietic cell transplantation after bispecific antibodies in non-Hodgkin lymphomas","volume":"58","author":"Pe\u00f1a","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"13","key":"2025082608215220900_bib52","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/bloodadvances.2024012916","article-title":"Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis","volume":"8","author":"Reynolds","year":"2024","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2025082608215220900_bib53","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood-2023-178321","article-title":"Low mortality from COVID-19 infection in patients with B-cell lymphoma after bispecific CD20xCD3 therapy [abstract]","volume":"142","author":"Kyvsgaard","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2025082608215220900_bib54","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4143\/crt.2023.738","article-title":"Impact of T-cell engagers on COVID-19-related mortality in B-cell lymphoma patients receiving B-cell depleting therapy","volume":"56","author":"Lee","year":"2024","journal-title":"Cancer Res Treat"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/16\/4180\/2406788\/blooda_adv-2024-015406-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/16\/4180\/2406788\/blooda_adv-2024-015406-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T12:22:04Z","timestamp":1756210924000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/16\/4180\/537379\/Impact-of-SARS-CoV-2-infection-on-bispecific"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":54,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,8,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015406","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,26]]},"published":{"date-parts":[[2025,8,14]]}}}